SOLVO is the exclusive commercial provider of B-CLEAR® kits and a provider of B-CLEAR® services in Europe

June 13th 2008: Qualyst, Inc.’s patented B-CLEAR^® sandwich-cultured hepatocyte technology is the only in vitro method which can evaluate hepatobiliary disposition of a compound, predict in vivo hepatic uptake and biliary clearance, and assess drug transporter-based inhibition. B-CLEAR^® technology can be used by pharmaceutical and biotechnology companies to address critical questions such as:

• What is the extent of a compound’s hepatic uptake and biliary excretion?
• What is the potential for in vivo biliary clearance (rat and human)?
• Are there interspecies differences in the hepatic uptake and biliary clearance of a compound and/or its metabolites?
• Which drug candidates have optimal transport properties?
• What transporters are involved in the hepatobiliary disposition of the compounds and their metabolites?

In vitro single transporter-drug interaction studies are conducted on SOLVO cell and membrane vesicles based systems.

• What is the potential for drug-drug interactions at the level of hepatobiliary transport?

The B-CLEAR^® technology can also be used to predict the potential of drugs to interact with the elimination of endogenous substrates (e.g., bilirubin, taurocholate) which may result in hepatotoxicity (cholestasis, jaundice) in vivo. Please find detailed information and some reference data of B-CLEAR® technology here: B-CLEAR^® technology.  

The following B-CLEAR^® products and services are available from SOLVO in Europe:

B-CLEAR^® Kits:

o        B-CLEAR^® -RT (Rat) Kit

o        B-CLEAR^® -HU (Human) Kit - under development

B-CLEAR^® Services:

Rat

o        Mrp2 efflux inhibition with Estradiol-17-beta-glucuronide as probe substrate

o        Mrp2 efflux inhibition with Bilirubin glucuronide as probe substrate

o        Bsep efflux inhibition with Taurocholate as probe substrate

o        Direct efflux measurements

o        Induction experiments - under development

Human

o        MRP2 efflux inhibition with Estradiol-17-beta-glucuronide as probe substrate- under development

o        MRP2 efflux inhibition with Bilirubin glucuronide as probe substrate

o        BSEP efflux inhibition with Taurocholate as probe substrate - under development

o        Direct efflux measurements

o       Induction experiments- under development 

For further information on B-CLEAR^® technology at SOLVO, please contact: b-clear@solvo.com .

With our best regards,
SOLVO Biotechnology
Business Development Team
bd@solvo.com